Verastem
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 88.5m | 2.1m | 2.6m | - | 6.5m | 18.9m | 53.8m |
| % growth | 407 % | (98 %) | 26 % | - | - | 193 % | 184 % |
| EBITDA | (47.6m) | (61.2m) | (71.7m) | (83.2m) | - | - | - |
| % EBITDA margin | (54 %) | (2982 %) | (2761 %) | - | - | - | - |
| Profit | (67.7m) | (71.2m) | (73.8m) | (87.4m) | (104m) | (117m) | (102m) |
| % profit margin | (77 %) | (3468 %) | (2843 %) | - | (1614 %) | (621 %) | (190 %) |
| EV / revenue | 4.1x | 181.9x | 32.6x | - | 15.6x | 5.3x | 1.9x |
| EV / EBITDA | -7.6x | -6.1x | -1.2x | -2.5x | - | - | - |
| R&D budget | 41.4m | 39.3m | 50.6m | 61.4m | - | - | - |
| R&D % of revenue | 47 % | 1917 % | 1948 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$16.0m | Series A | ||
$32.0m | Series B | ||
$20.0m | Series C | ||
| N/A | N/A | IPO | |
| N/A | $2.0m | Post IPO Equity | |
* | N/A | $44.1m | Post IPO Equity |
$25.0m | Post IPO Debt | ||
| N/A | $100m | Post IPO Equity | |
* | $25.0m | Post IPO Debt | |
* | $60.0m | Post IPO Equity | |
* | N/A | $55.0m | Post IPO Equity |
| Total Funding | AUD105m | ||
Related Content
Recent News about Verastem
EditVerastem Oncology, listed on NASDAQ under the ticker VSTM, is a biopharmaceutical company dedicated to developing innovative medicines aimed at improving the lives of cancer patients. The company focuses on creating therapies that target malignant cells directly and modulate the tumor microenvironment. Verastem's pipeline includes clinical-stage molecules such as the RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib, which are being evaluated in multiple clinical studies for various cancer types.
Verastem operates in the oncology market, serving patients diagnosed with different forms of cancer. The company’s business model revolves around the research, development, and commercialization of its proprietary cancer therapies. Revenue is generated through the sale of these therapies, as well as through strategic partnerships and licensing agreements.
Key clients include healthcare providers, hospitals, and cancer treatment centers that administer Verastem's therapies to patients. The company also collaborates with research institutions and participates in clinical trials to advance its drug development programs.
Keywords: biopharmaceutical, oncology, cancer therapies, clinical-stage, RAF/MEK inhibitor, FAK inhibitor, tumor microenvironment, clinical trials, NASDAQ VSTM, innovative medicines.